Activity Description

This consensus statement provides an in-depth summary of an expert panel discussion on the diagnosis and management of macular telangiectasia (MacTel) type 2. It focuses on achieving consensus among specialists on the pathophysiology, incidence, diagnosis, decision-making, emerging therapeutic treatments, and patient communication strategies to enhance the care of patients with MacTel type 2.

The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.

Release Date: 4/30/26
Expiration Date: 4/30/27

Target Audience

This accredited educational activity is designed for ophthalmologists.

Grant Support Statement

This activity is supported by an unrestricted educational grant from Neurotech.

Faculty  

Sophie Bakri, MD

• Professor and Chair
• Department of Ophthalmology
• Mayo Clinic
• Rochester, MN

W. Lloyd Clark, MD

• Vitreoretinal Surgeon and Partner
  
• NC Retina Associates
  
• North Carolina
  

Diana Do, MD

• Professor of Ophthalmology
• Vice Chair for Clinical Affairs
• Byers Eye Institute
• Stanford University

Dean Eliott, MD

• Stelios Evangelos Gragoudas Professor
• Department of Ophthalmology
• Harvard Medical School
• Boston, MA

Roger Goldberg, MD

• Bay Area Retina Associates
• Walnut Creek, CA

Dante Pieramici, MD

• Ophthalmologist
• California Retina Consultants
• Director California Retina Research Foundation
• Retina Consultants of America
• Santa Barbara, CA

Lejla Vajzovic, MD

• Professor of Ophthalmology
• Director of CME – Ophthalmology
• Duke University School of Medicine
• Durham, NC